Vascular endothelial growth factor gene therapy - HSCI

Drug Profile

Vascular endothelial growth factor gene therapy - HSCI

Alternative Names: Neovasculgen; PI-VEGF165; VEGF gene therapy - HSCI

Latest Information Update: 07 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Human Stem Cells Institute
  • Class Gene therapies; Ischaemic heart disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Peripheral arterial disorders
  • Clinical Phase Unknown Diabetic foot ulcer

Most Recent Events

  • 01 Aug 2015 Clinical trials in Diabetic foot ulcer in Russia (IM)
  • 05 Feb 2015 Human Stem Cell Institute plans a phase I/II trial for Peripheral nerve injuries (Adjuvant therapy) in Russia (NCT02352649)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top